StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Zevra Therapeutics's price to book ratio was 3.2× on Nov 11, 2026, against 3.6× a year earlier. Over the last 5 years it ranged from 1.3× to 14.8×, with a median of 3.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.2×−0.6
2025Dec 31, 20253.8×−2.6
2024Dec 31, 20246.4×+2.5
2023Dec 29, 20233.9×+2.2
2022Dec 30, 20221.7×−0.6
2021Dec 31, 20212.3×−160.4
2016Oct 31, 2016162.7×+95.6
2015Oct 30, 201567.2×–

More Zevra Therapeutics figures

See a number that looks wrong?